GLOBAL BRONCHITIS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Bronchitis Treatment Market, By Type (Acute Bronchitis and Chronic Bronchitis), By Treatment (Drugs and Oxygen Therapy), By Drug Class (Anti-Inflammatory Drugs, Antibiotics, Bronchodilators, Mucolytic), By Route of Administration (Oral, Parenteral, Inhalers/Nasal sprays, Others), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In 08 July 2024, CSA Medical Inc., the developer of The RejuvenAir System utilizing liquid nitrogen spray cryotherapy, had completed patient enrolment in its SPRAY-CB pivotal trial. This double-blind, sham-controlled clinical trial enrolled 210 patients globally for the treatment of COPD with Chronic Bronchitis.
In June 2023, Galvanize Therapeutics, Inc., a pioneer in advancing pulsed electric field (PEF) therapies for conditions including COPD, soft tissue issues, and cardiac arrhythmias, finished enrolling participants for the RheSolve pivotal trial. This trial assesses the RheOx Bronchial Rheoplasty System as a potential treatment for symptoms of chronic bronchitis.
In February 2022, Zydus, a division of CadilaHealthcare, a global lifesciences company, announced that its U.S. subsidiary had received final approval from the U.S. FDA to market roflumilast tablets in 500 mcg strength and tentative approval for roflumilast tablets. These tablets are indicated for reducing the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
In September 2021, Lincoln Pharmaceuticals Ltd, a pharmaceutical company, acquired a facility in India specializing in the production of antibiotics used to treat pneumonia and bronchitis